Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ribomic Inc. (4591.T)
Tokyo, JP
Ribomic Inc. is a Japanese biopharmaceutical company dedicated to identifying and advancing medicinal compounds. The firm employs RNA aptamers in its drug development efforts, targeting various significant health issues such as wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma. Furthermore, Ribomic manufactures specialized separating agents used for the affinity purification of human IgG and Fc-fusion proteins. Established in 2003, the company's main operations are based in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.33% | -8.64% | -13.95% | -9.76% | -11.90% | -5.13% | -15.91% | -59.12% | -75.97% | -90.82% | -96.11% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+42.4% ★ Q1'26: +2,202.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+8.5% Q1'26: -13.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-39,914.7% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-40,237.7% Q1'26: -18,619.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-8,658.2% Q1'26: -12,019.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+22.8% Q1'26: +20.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
479.87M
est: 480.00M (0.0%)
|
121.91M
est: 120.00M (+1.6%)
|
93.77M
est: 430.00M (-78.2%)
|
64.73M
est: 70.00M (-7.5%)
|
7.95M
est: 5.00M (+59.0%)
|
121.39M
est: 100.00M (+21.4%)
|
91.96M
est: 90.00M (+2.2%)
|
80.91M
est: 80.00M (+1.1%)
|
65.97M
est: 100.00M (-34.0%)
|
—
est: 100.00M (-100.0%)
|
| EBITDA |
24.97M
est: -288.00M (+108.7%)
|
-517.79M
est: -72.00M (-619.2%)
|
-749.00M
est: -258.00M (-190.3%)
|
-873.03M
est: -42.00M (-1,978.7%)
|
-898.96M
est: -3.00M (-29,865.4%)
|
-895.50M
est: -60.00M (-1,392.5%)
|
-1.21B
est: -54.00M (-2,145.0%)
|
-1.73B
est: -48.00M (-3,509.6%)
|
-1.79B
est: -60.00M (-2,875.9%)
|
-1.11B
est: -60.00M (-1,742.8%)
|
| EBIT |
6.18M
est: -288.00M (+102.1%)
|
-532.39M
est: -72.00M (-639.4%)
|
-785.90M
est: -258.00M (-204.6%)
|
-899.89M
est: -42.00M (-2,042.6%)
|
-928.63M
est: -3.00M (-30,854.2%)
|
-914.58M
est: -60.00M (-1,424.3%)
|
-1.24B
est: -54.00M (-2,195.6%)
|
-1.75B
est: -48.00M (-3,541.9%)
|
-1.79B
est: -60.00M (-2,876.7%)
|
-1.12B
est: -60.00M (-1,760.3%)
|
| Net Income |
10.30M
est: 36.38M (-71.7%)
|
-323.31M
est: -1.41B (+77.0%)
|
-646.60M
est: -1.13B (+42.7%)
|
-753.05M
est: -2.66B (+71.7%)
|
-836.62M
est: -2.40B (+65.2%)
|
-855.04M
est: -2.38B (+64.1%)
|
-1.19B
est: -2.13B (+44.4%)
|
-1.68B
est: -3.44B (+51.0%)
|
-1.65B
est: -2.12B (+22.1%)
|
-1.02B
est: -2.12B (+51.7%)
|
| SGA |
189.52M
est: 18.85B (-99.0%)
|
217.97M
est: 4.71B (-95.4%)
|
266.64M
est: 16.89B (-98.4%)
|
275.66M
est: 2.75B (-90.0%)
|
319.22M
est: 196.37M (+62.6%)
|
316.48M
est: 3.93B (-91.9%)
|
303.03M
est: 3.53B (-91.4%)
|
311.16M
est: 3.14B (-90.1%)
|
360.71M
est: 3.93B (-90.8%)
|
351.74M
est: 3.92B (-91.0%)
|
| EPS |
0.88
est: 0.90 (-2.2%)
|
-24.92
est: -34.80 (+28.4%)
|
-48.83
est: -27.90 (-75.0%)
|
-55.61
est: -65.80 (+15.5%)
|
-58.22
est: -59.40 (+2.0%)
|
-53.62
est: -59.00 (+9.1%)
|
-46.17
est: -52.80 (+12.6%)
|
-59.95
est: -85.00 (+29.5%)
|
-53.14
est: -52.50 (-1.2%)
|
-28.70
est: -52.50 (+45.3%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hisato Oiwa | Executive Officer, Head of Management Headquarters & Director | — | male |
| Masayuki Miyazaki | Executive Officer, GM of Business Administration Department | — | male |
| Yoshikazu Nakamura | Chief Executive Officer, President & Representative Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4591.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
